Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report By Technology (Microbiology Culture, PCR), By End-use (Hospitals, Diagnostic Laboratories), By Pathogen, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
Antimicrobial Resistance Diagnostics Market Growth & Trends
The global antimicrobial resistance diagnostics market size is expected treach USD 6.70 billion by 2030, registering a CAGR of 6.55% from 2025 t2030, according ta new report by Grand View Research, Inc. The increased risk of developing drug-resistant bacterial infections, especially in healthcare facilities, and increasing government & non-government bodies’ efforts tcombat the threat of AMR are the major factor contributing tmarket growth. In addition, various strategic initiatives undertaken by leading market players tmanage antimicrobial resistance are alscontributing tmarket expansion. For instance, in March 2021, bioMerieux and GIZ collaborated tsupport the Nigerian center for disease control tstrengthen the fight against AMR.
The rising adoption of rapid testing and PoC tests for drug-resistant bacterial infections is anticipated taugment the market over the projected period. Moreover, leading market players such as Danaher, Abbott, and others have a robust product portfoliof rapid diagnostic tests for antimicrobial-resistant infections. Furthermore, the increasing involvement of non-government bodies such as AMR Industry Alliance is assisting regulatory bodies tmake strategies tboost the development of diagnostic solutions tmanage antimicrobial resistance.
Increasing funding for the development of novel and automated test solutions for the diagnosis of antimicrobial-resistant infections is anticipated tboost market growth over the forecast period. For instance, in May 2022, the European Investment Bank funded more than USD 24 million tPOCARED Diagnostics for the R&D of fully automated testing of microbial diseases. POCARED Diagnostics is involved in the development of novel microbiology tests that can provide results within hours.
Antimicrobial resistance is expected trise in the coming years. Hence, demand for accurate & fast testing options is expected tincrease for the effective management and progression monitoring of antimicrobial resistance. According tthe CDC, the annual direct healthcare expenditure of antimicrobial resistance is around USD 20 billion in the U.S. High cost of disease management is driving the demand for rapid tests for the diagnosis of infections at an early stage.
Key market players are continuously involved in the development of novel tests tstrengthen their market position. Moreover, other strategies such as acquisitions, partnerships, and collaborations are alsadopted by leading players texpand their product portfoliin different parts of the globe. For instance, in August 2022, Accelerate Diagnostics and BD announced a collaboration tcombat the threat of antimicrobial resistance. As per the deal, BD will provide Accelerate Diagnostics rapid diagnostic solutions for antibiotics-associated resistance tits vast customers.
Antimicrobial Resistance Diagnostics Market Report Highlights
Antimicrobial Resistance Diagnostics Market Growth & Trends
The global antimicrobial resistance diagnostics market size is expected treach USD 6.70 billion by 2030, registering a CAGR of 6.55% from 2025 t2030, according ta new report by Grand View Research, Inc. The increased risk of developing drug-resistant bacterial infections, especially in healthcare facilities, and increasing government & non-government bodies’ efforts tcombat the threat of AMR are the major factor contributing tmarket growth. In addition, various strategic initiatives undertaken by leading market players tmanage antimicrobial resistance are alscontributing tmarket expansion. For instance, in March 2021, bioMerieux and GIZ collaborated tsupport the Nigerian center for disease control tstrengthen the fight against AMR.
The rising adoption of rapid testing and PoC tests for drug-resistant bacterial infections is anticipated taugment the market over the projected period. Moreover, leading market players such as Danaher, Abbott, and others have a robust product portfoliof rapid diagnostic tests for antimicrobial-resistant infections. Furthermore, the increasing involvement of non-government bodies such as AMR Industry Alliance is assisting regulatory bodies tmake strategies tboost the development of diagnostic solutions tmanage antimicrobial resistance.
Increasing funding for the development of novel and automated test solutions for the diagnosis of antimicrobial-resistant infections is anticipated tboost market growth over the forecast period. For instance, in May 2022, the European Investment Bank funded more than USD 24 million tPOCARED Diagnostics for the R&D of fully automated testing of microbial diseases. POCARED Diagnostics is involved in the development of novel microbiology tests that can provide results within hours.
Antimicrobial resistance is expected trise in the coming years. Hence, demand for accurate & fast testing options is expected tincrease for the effective management and progression monitoring of antimicrobial resistance. According tthe CDC, the annual direct healthcare expenditure of antimicrobial resistance is around USD 20 billion in the U.S. High cost of disease management is driving the demand for rapid tests for the diagnosis of infections at an early stage.
Key market players are continuously involved in the development of novel tests tstrengthen their market position. Moreover, other strategies such as acquisitions, partnerships, and collaborations are alsadopted by leading players texpand their product portfoliin different parts of the globe. For instance, in August 2022, Accelerate Diagnostics and BD announced a collaboration tcombat the threat of antimicrobial resistance. As per the deal, BD will provide Accelerate Diagnostics rapid diagnostic solutions for antibiotics-associated resistance tits vast customers.
Antimicrobial Resistance Diagnostics Market Report Highlights
- The PCR segment dominated the market and accounted for the largest revenue share of 24.19% in 2024. Advancements in PCR technology, along with its widespread adoption due tits high accuracy, are key factors driving the significant share of this segment.
- In 2024, the methicillin resistant staphylococcus aureus segment held the largest market share at 28.33%. The rising incidence of MRSA in hospital settings is a key driver for the expansion of this segment.
- In 2024, the hospitals segment led the market, accounting for 48.07% of the revenue share. The growth of this segment is driven by several factors, including the rising incidence of hospital-acquired infections and increased hospitalizations due tantimicrobial-resistant (AMR) infections, which often lead tprolonged hospital stays.
- North America antimicrobial resistance diagnostics market dominated the overall global market with a revenue share of 42.03% in 2024.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Pathogen
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increase in risk of developing drug - resistant bacterial infections
3.2.1.2. Introduction of novel technologies to diagnose AMR infections
3.2.1.3. Favorable government initiatives
3.2.2. Market Restraint Analysis
3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
3.3. Antimicrobial Resistance Diagnostics Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Antimicrobial Resistance Diagnostics Market: Technology Movement Analysis
4.3. Antimicrobial Resistance Diagnostics Market by Technology Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Microbiology Culture
4.5.1. Microbiology Culture Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Immunoassay
4.6.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.2. PCR
4.6.2.1. PCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.3. NGS
4.6.3.1. NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.4. Mass Spectrometry
4.6.4.1. Mass Spectrometry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.5. Rapid & Point of Care
4.6.5.1. Rapid & Point of Care Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.6. Others
4.6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET: PATHOGEN ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Antimicrobial Resistance Diagnostics Market: Pathogen Movement Analysis
5.3. Antimicrobial Resistance Diagnostics Market by Pathogen Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Drug Resistant Streptococcus Pneumoniae (DRSP)
5.5.1. Drug Resistant Streptococcus Pneumoniae (DRSP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Drug Resistant Campylobacter (DRC)
5.6.1. Drug Resistant Campylobacter (DRC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Clostridium Difficile (CD)
5.7.1. Clostridium Difficile (CD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Drug Resistant Neisseria Gonorrhoeae (DRNG)
5.8.1. Drug Resistant Neisseria Gonorrhoeae (DRNG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Drug Resistant Salmonella (DRNTS)
5.9.1. Drug Resistant Salmonella (DRNTS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.10. Others
5.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Antimicrobial Resistance Diagnostics Market: End Use Movement Analysis
6.3. Antimicrobial Resistance Diagnostics Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Hospitals
6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Diagnostic Laboratories
6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Pharmaceutical & Biotechnology Companies
6.7.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Others
6.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
8.4.1. bioMerieux
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. F. Hoffmann - La Roche Ltd
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Abbott
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. BD
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Danaher
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Accelerate Diagnostics, Inc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Molsid
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Vela Diagnostics
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Visby Medical, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Hologic, Inc.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Pathogen
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increase in risk of developing drug - resistant bacterial infections
3.2.1.2. Introduction of novel technologies to diagnose AMR infections
3.2.1.3. Favorable government initiatives
3.2.2. Market Restraint Analysis
3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
3.3. Antimicrobial Resistance Diagnostics Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Antimicrobial Resistance Diagnostics Market: Technology Movement Analysis
4.3. Antimicrobial Resistance Diagnostics Market by Technology Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Microbiology Culture
4.5.1. Microbiology Culture Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Immunoassay
4.6.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.2. PCR
4.6.2.1. PCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.3. NGS
4.6.3.1. NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.4. Mass Spectrometry
4.6.4.1. Mass Spectrometry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.5. Rapid & Point of Care
4.6.5.1. Rapid & Point of Care Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.6. Others
4.6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET: PATHOGEN ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Antimicrobial Resistance Diagnostics Market: Pathogen Movement Analysis
5.3. Antimicrobial Resistance Diagnostics Market by Pathogen Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Drug Resistant Streptococcus Pneumoniae (DRSP)
5.5.1. Drug Resistant Streptococcus Pneumoniae (DRSP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Drug Resistant Campylobacter (DRC)
5.6.1. Drug Resistant Campylobacter (DRC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Clostridium Difficile (CD)
5.7.1. Clostridium Difficile (CD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Drug Resistant Neisseria Gonorrhoeae (DRNG)
5.8.1. Drug Resistant Neisseria Gonorrhoeae (DRNG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Drug Resistant Salmonella (DRNTS)
5.9.1. Drug Resistant Salmonella (DRNTS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.10. Others
5.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Antimicrobial Resistance Diagnostics Market: End Use Movement Analysis
6.3. Antimicrobial Resistance Diagnostics Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Hospitals
6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Diagnostic Laboratories
6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Pharmaceutical & Biotechnology Companies
6.7.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Others
6.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
8.4.1. bioMerieux
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. F. Hoffmann - La Roche Ltd
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Abbott
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. BD
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Danaher
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Accelerate Diagnostics, Inc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Molsid
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Vela Diagnostics
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Visby Medical, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Hologic, Inc.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
